147 related articles for article (PubMed ID: 31749296)
21. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
[TBL] [Abstract][Full Text] [Related]
22. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
[TBL] [Abstract][Full Text] [Related]
24. Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection.
Stalter RM; Pintye J; Mugwanya KK
Expert Opin Drug Saf; 2021 Nov; 20(11):1367-1373. PubMed ID: 33998936
[No Abstract] [Full Text] [Related]
25. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
[TBL] [Abstract][Full Text] [Related]
26. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
27. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
Cressey TR; Siriprakaisil O; Kubiak RW; Klinbuayaem V; Sukrakanchana PO; Quame-Amaglo J; Okochi H; Tawon Y; Cressey R; Baeten JM; Gandhi M; Drain PK
Int J Infect Dis; 2020 Aug; 97():365-370. PubMed ID: 32553717
[TBL] [Abstract][Full Text] [Related]
28. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.
Wahl A; Ho PT; Denton PW; Garrett KL; Hudgens MG; Swartz G; O'Neill C; Veronese F; Kashuba AD; Garcia JV
Sci Rep; 2017 Feb; 7():41098. PubMed ID: 28145472
[TBL] [Abstract][Full Text] [Related]
29. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model.
Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321
[TBL] [Abstract][Full Text] [Related]
30. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
31. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
[TBL] [Abstract][Full Text] [Related]
32. Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.
Mathialagan S; Piotrowski MA; Tess DA; Feng B; Litchfield J; Varma MV
Drug Metab Dispos; 2017 Apr; 45(4):409-417. PubMed ID: 28179375
[TBL] [Abstract][Full Text] [Related]
33. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
Baum MM; Butkyavichene I; Churchman SA; Lopez G; Miller CS; Smith TJ; Moss JA
Int J Pharm; 2015 Nov; 495(1):579-587. PubMed ID: 26386138
[TBL] [Abstract][Full Text] [Related]
34. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
[TBL] [Abstract][Full Text] [Related]
35. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
36. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
37. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012-2017.
Sullivan PS; Giler RM; Mouhanna F; Pembleton ES; Guest JL; Jones J; Castel AD; Yeung H; Kramer M; McCallister S; Siegler AJ
Ann Epidemiol; 2018 Dec; 28(12):833-840. PubMed ID: 30037634
[TBL] [Abstract][Full Text] [Related]
38. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
[TBL] [Abstract][Full Text] [Related]
40. Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Cressey TR; Avihingsanon A; Halue G; Leenasirimakul P; Sukrakanchana PO; Tawon Y; Jaisieng N; Jourdain G; Podany AT; Fletcher CV; Klinbuayaem V; Bowonwatanuwong C
Clin Infect Dis; 2015 Aug; 61(4):633-9. PubMed ID: 25921689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
